The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies.
 
Justin C Moser
Honoraria - Caris Life Sciences
 
Mark Voskoboynik
Consulting or Advisory Role - AstraZeneca
 
Nehal J. Lakhani
Consulting or Advisory Role - Innovent Biologics
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Celgene (Inst); Celgene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Formation Biologics (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics; Innovent Biologics (Inst); Jounce Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
 
Michael Millward
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Dizal Pharma (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MaxiNovel (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Therapim (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Diwakar Davar
Honoraria - Array BioPharma; Immunocore; Instil Bio; Merck; Tesaro; Vedanta Biosciences
Consulting or Advisory Role - Instil Bio; Shionogi (I); Vedanta Biosciences
Research Funding - Bristol-Myers Squibb; CellSight Technologies; Checkmate Pharmaceuticals; medpacto; Merck; Tesaro; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231
 
Wael A. Harb
No Relationships to Disclose
 
Jing Yang
Employment - Alpine Immune Sciences
 
Gary Means
Employment - Alpine Immune Sciences
 
Kristi Manjarrez
Employment - Alpine Immune Sciences
 
Almudena Tercero
Employment - Alpine Immune Sciences
 
Hany Zayed
Employment - Alpine Immune Sciences
 
Jan Hillson
Employment - Alpine Immune Sciences
 
Christine Dela Cruz
No Relationships to Disclose
 
Graciela Noemi Perez
No Relationships to Disclose
 
Stanford L. Peng
Employment - Alpine Immune Sciences